Skip to content
value.today

Immuron Ltd

IMRN
$9 Mmarket cap on Aug 1, 2026-18.2% since Jan 2024
Compare
World rank
#26,015
Revenue
$5 M
For year ending June-2025
Net income
$-3 M
-71.6% margin
SEC filing
Employees
—

Immuron Ltd in brief

Immuron Ltd is a listed company in the Biotechnology industry, based in Australia. Its market value was $9 M on 1 August 2026, which makes it the 26,015th largest listed company in the world and the 737th largest in Australia on this site. In the year to June 2025 it had sales of $5 M and a net loss of $3 M. Steven George Lydeamore is its chief executive. Its largest product and service lines by sales in 2026 were Travelan (99%), ProIBS (1%) and Protectyn (under 1%). Its shares trade under the symbol IMRN (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Immuron Ltd

Immuron Limited was incorporated as an Australian Public Company, Limited by Shares under the name Anadis Limited (and changed its name to Immuron Limited in December 2008) in Victoria, Australia under the laws of the Commonwealth of Australia in 1994 and our ordinary shares have been listed on the ASX since April 30, 1999. Our ADSs and Warrants have traded on The NASDAQ Capital Market since June 13, 2017, with the Warrants delisted in June 2022 in connection with their expiration. We currently operate under the laws of the Commonwealth of Australia, including the Corporations Act of 2001. Our principal executive office is located at Level 3, 62 Lygon Street, Carlton South, Victoria, Australia 3053 and our telephone number is +61 (0)3 8892 4854. Our agent for service in the U.S. is Puglisi & Associates, 850 Library Avenue, Suite 204, Newark, DE 19711. Our website address is www.immuron.com.au. The information contained on or accessible through our website is not a part of or incorporated by reference into this annual report and the inclusion of our website address herein is an inactive textual reference only.

From the company's annual report filed with the US SEC: read the report

Immuron Ltd timeline

2 events, 2016–2017
  1. 2016
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2017
  4. 🔔
    · approximate
    Initial public offering on Nasdaq

Events of Immuron Ltd from SEC EDGAR and the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$11 M$22 M$32 M$43 M2020202120222023202420252026

World rank over time

▲ up 2,453 places since 2020
2020-01-01: #25515#25,51520202021-01-01: #21371#21,37120212022-01-07: #30753#30,75320222022-12-25: #31196#31,19620222023-07-30: #31307#31,30720232024-01-05: #30854#30,85420242026-03-08: #13053#13,05320262026-08-01: #23062#23,0622026

Rank in Australia: #596 (Jan 2020) · #531 (Jan 2021) · #1,276 (Jan 2022) · #951 (Dec 2022) · #1,015 (Jul 2023) · #1,078 (Jan 2024) · #7 (Mar 2026) · #731 (Aug 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
1.9×
Price / book
1.7×
Free cash flow yield
-42.8%
Net margin (TTM)
-71.6%
Operating margin
-73.3%
Return on equity
-64.1%
Liabilities / assets
20.4%
Revenue growth
+47.0%
R&D / revenue
49.4%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Jun 2018: revenue $1M, net income $-2M$1MFY18Fiscal year ending Jun 2019: revenue $1M, net income $-3M$1MFY19Fiscal year ending Jun 2020: revenue $2M, net income $-2M$2MFY20Fiscal year ending Jun 2021: revenue $0M, net income $-6M$0MFY21Fiscal year ending Jun 2022: revenue $1M, net income $-2M$1MFY22Fiscal year ending Jun 2023: revenue $1M, net income $-3M$1MFY23Fiscal year ending Jun 2024: revenue $3M, net income $-5M$3MFY24Fiscal year ending Jun 2025: revenue $5M, net income $-3M$5MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Jun 2025$5M+47.0%$-3M$-3M-71.6%
Jun 2024$3M+165.3%$-4M$-5M-141.7%
Jun 2023$1M+116.1%$-2M$-3M-210.7%
Jun 2022$1M+409.1%$-2M$-2M-369.6%
Jun 2021$0M-93.5%$-6M$-6M-5681.8%
Jun 2020$2M+17.4%$-2M$-2M-116.0%
Jun 2019$1M+27.4%$-3M$-3M-231.3%
Jun 2018$1M—$-2M$-2M-210.6%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Jun 2025$-4M——$-1.46—
Jun 2024$-4M$0M$-4M$-1.99—
Jun 2023$-2M$0M$-2M$-1.12—
Jun 2022$-2M$0M$-2M$-0.91—
Jun 2021$-3M$0M$-3M$-2.83—
Jun 2020$-2M$0M$-2M——
Jun 2019$-1M$0M$-1M——
Jun 2018$-3M$0M$-3M——

SEC filings

Official filings of Immuron Ltd with the US Securities and Exchange Commission.

Annual results

Revenue
$5 M
Operating income
$-3 M
Net income
$-3 M

For year ending June-2025 · source: SEC filing

Balance sheet

Total assets
$7 M
Total liabilities
$1 M
Total equity
$5 M

As of June-2025

Top 8 institutional investors in Immuron Ltd#

As of Sep 30, 2026
8 institutions held 157,425 shares (about 1.9% of the shares outstanding) on Sep 30, 2026. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 8 largest institutional investors in Immuron Ltd
#InstitutionShares heldChange (shares)% heldValueFiled
1BNP Paribas Financial Markets49,549+44,349 (+852.87%)0.59%$0 MNov 12, 2026
2HRT Financial LP33,396+12,812 (+62.24%)0.40%$0 MNov 13, 2026
3Jane Street Group, LLC33,255New0.40%$0 MNov 12, 2026
4UBS Group AG22,512+22,149 (+6101.65%)0.27%$0 MNov 10, 2026
5Citadel Advisors LLC14,690-28,433 (-65.93%)0.18%$0 MNov 16, 2026
6Rhumbline Advisers3,835-3,532 (-47.94%)0.05%$0 MNov 10, 2026
7Royal Bank Of Canada160New0.00%$0 MNov 16, 2026
8Caitong International Asset Management Co., Ltd28New0.00%$0 MOct 29, 2026

Markets and events: Immuron Ltd#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
26,156
1.65 days to cover
Reg SHO threshold list
10 days
in the last 90 days
Shares sold short, last 24 reportsAll stocks →

Fails to deliver

  • : 217 shares at $0.91
  • : 111 shares at $0.94
  • : 320 shares at $0.95
  • : 555 shares at $0.95
  • : 490 shares at $0.96

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Immuron Ltd scorecard#

Passes 7 of the 15 checks that could be worked out: strongest in growth (4 of 6), weakest in profitability (1 of 5). Fiscal year 2025; market cap of Aug 1, 2026.

  • Valuationnot known
    • –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
    • –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
    • –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
  • Growth4 of 6
    • ✓Revenue grew in the newest year47.0%Revenue up 47.0% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years103.5%103.5% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median103.5%103.5% a year against Biotechnology's median of 12.9% (181 companies).
    • ✗Earnings per share grew in the newest year-1.46 vs -1.99Diluted EPS -1.46 in fiscal 2025 against -1.99 the year before (report's currency).
    • ✗Net income higher than five years earlier-$3 M-$3 M in fiscal 2025 against -$2 M in 2020.
    • ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2025.
  • Profitability1 of 5
    • ✗Profitable in the newest year-$3 MNet income -$3 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-73.3%-73.3% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%-49.2%-49.2% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-73.3%-73.3% in fiscal 2025 against -371.4% in 2022.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities5.1×Current ratio 5.11 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-7.46Z-score -7.46 (distress zone) for fiscal 2025.
  • Shareholder returns1 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✓Share count up no more than 2% in a year1.4%Diluted shares up 1.4% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Immuron Ltd's statements, beside the median of Biotechnology.

Immuron Ltd: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-73.3%-60.5%
Net margin-71.6%-68.9%
Return on equity-49.2%-61.0%
Revenue growth, 3 years a year103.5%12.9%
Revenue growth47.0%15.8%

1of 8on the Piotroski tests of financial strength

  • Net loss of $3 million, the 10th loss-making year in a row.
  • Revenue has grown 4 years in a row.

Immuron Ltd: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in AUD thousands; per-share figures in AUD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Immuron Ltd: statements by fiscal year
PeriodTrendFY 2025to Jun 30, 2025FY 2024to Jun 30, 2024FY 2023to Jun 30, 2023FY 2022to Jun 30, 2022FY 2021to Jun 30, 2021FY 2020to Jun 30, 2020FY 2019to Jun 30, 2019FY 2018to Jun 30, 2018FY 2017to Jun 30, 2017FY 2016to Jun 30, 2016
Income statement
Revenue7,2874,9031,8057651462,519r2,016r1,457r1,3961,001
Cost of revenue2,5221,56649624251689667419338301
Gross profit4,7653,3371,309524951,8301,7201,4241,059700
Research and development3,5975,3752,5926581,3671,1791,0452,2574,6313,624
Selling, general and administrative———————282408134
Selling and marketing712339r260r245171236210169r135r939
General and administrative————3,9793,7043,6941,3371,3821,321
Operating income−5,345−5,801−3,569−2,870−8,380−2,906−4,656r−3,046r−6,723—
Interest and finance income136328116229.2—0.01.28.412
Interest expense and finance costs7.37.69.76.21422—24r90r342
Provision for credit losses——−431—760—————
Share of profit of associates—−1,456−324———————
Income before tax−5,216−6,937−3,787−2,854−8,384−2,927−4,656r−3,069r−6,804−7,069
Net income including minority interests−5,216−6,937−3,787−2,854−8,384−2,927−4,656r−3,069r−6,804−7,069
Net income attributable to shareholders−5,216−6,937−3,787−2,854−8,384−2,927−4,656———
Earnings per share, basic-2.26-3.04-1.66-1.25-3.79—————
Earnings per share, diluted-2.26-3.04-1.66-1.25-3.79—————
Shares, weighted average (basic)231228228228——————
Shares, weighted average (diluted)231228228228——————
Balance sheet
Cash and cash equivalents2,83111,65717,16022,11025,0473,2505,1204,7273,9952,291
Short-term investments——404———————
Receivables1,9261,3884176633353289691,6831,768—
Inventory1,7721,5858403272937985444982,336—
Other current assets3,48797158572783349142168—
Current assets10,01514,72620,40923,67225,7534,4096,6827,0508,268—
Property, plant and equipment1141542002273471172019—
Right-of-use (leased) assets—1401802071958————
Investments in associates——159———————
Non-current assets1158241,5791,1841,3001,7931,8792,19219—
Total assets10,13015,55021,98824,85627,0536,2028,5629,2438,2868,827
Accounts payable1,5292,1361,1931,1617583841,0926891,290—
Current liabilities1,9662,6992,2191,5031,1225161,1968031,712—
Lease liabilities (non-current)—133150175—19————
Non-current liabilities95142152175364215———
Total liabilities2,0612,8412,3711,6781,1585581,2118031,7123,887
Retained earnings−82,443−78,968−72,055−68,425−65,933−57,916−57,239r−52,539−49,528—
Total equity8,06912,70919,61723,17725,8955,6447,3518,4396,575—
Shares outstanding——0.0————1308075
Cash-flow statement
Depreciation and amortization5046492744445.35.04.93.9
Share-based compensation3043.322795—73r1,34460r523r−2,079
Cash from operating activities−6,137−5,880−2,595−3,148−4,079−3,147−1,799−3,505r−6,942r−5,158
Capital expenditure—−0.2−7.7−10−6.6−0.9−2.0−6.6−5.7−2.4
Cash from investing activities−2,900328−2,621122.6−0.9−2.0−5.3r2.7r−2.4
Debt issued————213——5005002,950
Debt repaid————−213−367—−866−2,192−1,077
Shares issued—24——29,2811,9572,8945,472r12,5252,483
Shares bought back——−79———————
Cash from financing activities2000.8−45−4226,4801,1572,0694,349r8,604r4,335
Exchange-rate effect on cash1149311242−607122124−10740—
Change in cash−8,838−5,552−5,261−3,17922,404−1,9912698391,664−825
Report20-F20-F20-F20-F20-F20-F20-F20-F20-F20-F

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Immuron Ltd sells: revenue by product line, fiscal 2026#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2025. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Travelan$5 M99%
  • ProIBS$0 M1.1%
  • Protectyn$0 M0.3%

Business segments

  • Hyper-Immune Products$5 M100%

Source: SEC annual report (XBRL data) · as of Jun 30, 2026

How Immuron Ltd compares in Biotechnology

  • Market cap$9 M · higher than 9% of 726
  • Revenue$5 M · higher than 35% of 647
  • Net margin-71.6% · higher than 47% of 408
  • Revenue growth47.0% · higher than 71% of 438
  • Price / sales1.9× · lower than 86% of 339
  • Price / book1.7× · lower than 62% of 534
  • FCF yield-42.8% · higher than 27% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Immuron Ltd🇦🇺$9 M—-71.6%+47.0%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Aug 1, 2026
Annual results:
For year ending June-2025
Balance sheet:
As of June-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Immuron Ltd? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Immuron Ltd's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Immuron Ltd? Suggest a correction